Literature DB >> 10081672

Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.

L Zeitlin1, R A Cone, K J Whaley.   

Abstract

Passive immunization with antibodies has been shown to prevent a wide variety of diseases. Recent advances in monoclonal antibody technology are enabling the development of new methods for passive immunization of mucosal surfaces. Human monoclonal antibodies, produced rapidly, inexpensively, and in large quantities, may help prevent respiratory, diarrheal, and sexually transmitted diseases on a public health scale.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10081672      PMCID： PMC2627706          DOI： 10.3201/eid0501.990107

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN： 1080-6040            Impact factor:   6.883


  57 in total

Review 1.  Interaction of antigens and antibodies at mucosal surfaces.

Authors:  M E Lamm
Journal:  Annu Rev Microbiol       Date:  1997       Impact factor: 15.500

2.  Quantitative evaluation of the gastrointestinal absorption of protein into the blood and lymph circulation.

Authors:  Y Tsume; Y Taki; T Sakane; T Nadai; H Sezaki; K Watabe; T Kohno; S Yamashita
Journal:  Biol Pharm Bull       Date:  1996-10       Impact factor: 2.233

3.  Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus.

Authors:  G P Davidson; P B Whyte; E Daniels; K Franklin; H Nunan; P I McCloud; A G Moore; D J Moore
Journal:  Lancet       Date:  1989-09-23       Impact factor: 79.321

4.  Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.

Authors:  C O Tacket; S B Binion; E Bostwick; G Losonsky; M J Roy; R Edelman
Journal:  Am J Trop Med Hyg       Date:  1992-09       Impact factor: 2.345

5.  Lymphocytes protect against and are not required for reovirus-induced myocarditis.

Authors:  B Sherry; X Y Li; K L Tyler; J M Cullen; H W Virgin
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.

Authors:  F M Apter; P Michetti; L S Winner; J A Mack; J J Mekalanos; M R Neutra
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

7.  Protection against keratoconjunctivitis shigellosa induced by immunization with outer membrane proteins of Shigella spp.

Authors:  G Adamus; M Mulczyk; D Witkowska; E Romanowska
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

8.  Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library.

Authors:  T J Vaughan; A J Williams; K Pritchard; J K Osbourn; A R Pope; J C Earnshaw; J McCafferty; R A Hodits; J Wilton; K S Johnson
Journal:  Nat Biotechnol       Date:  1996-03       Impact factor: 54.908

9.  Monoclonal antibody-mediated protection and neutralization of motility in experimental Proteus mirabilis infection.

Authors:  R C Harmon; R L Rutherford; H M Wu; M S Collins
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

10.  Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.

Authors:  G Nussbaum; R Yuan; A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307
View more
  32 in total

1.  Swift antibodies to counter emerging viruses.

Authors:  Dennis R Burton; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

2.  Administration of antibody to the lung protects mice against pneumonic plague.

Authors:  Jim Hill; Jim E Eyles; Stephen J Elvin; Gareth D Healey; Roman A Lukaszewski; Richard W Titball
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.

Authors:  Samuel K Lai; D Elizabeth O'Hanlon; Suzanne Harrold; Stan T Man; Ying-Ying Wang; Richard Cone; Justin Hanes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-23       Impact factor: 11.205

4.  Could the GI tract be a better portal for antibody therapy?

Authors:  S J Green; Jon Brendsel
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

5.  Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.

Authors:  Ann R Hunt; Richard A Bowen; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  Virology       Date:  2011-04-13       Impact factor: 3.616

6.  The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.

Authors:  Liam B King; Marnie L Fusco; Andrew I Flyak; Philipp A Ilinykh; Kai Huang; Bronwyn Gunn; Robert N Kirchdoerfer; Kathryn M Hastie; Amandeep K Sangha; Jens Meiler; Galit Alter; Alexander Bukreyev; James E Crowe; Erica Ollmann Saphire
Journal:  Cell Host Microbe       Date:  2018-01-10       Impact factor: 21.023

7.  Engineering drug delivery systems to overcome mucosal barriers for immunotherapy and vaccination.

Authors:  Jacob C McCright; Katharina Maisel
Journal:  Tissue Barriers       Date:  2019-11-28

8.  Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis.

Authors:  Michael W Riggs; Deborah A Schaefer; Sushila J Kapil; Lise Barley-Maloney; Lance E Perryman
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

9.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 10.  Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces.

Authors:  Jiri Mestecky; Michael W Russell
Journal:  Immunol Lett       Date:  2009-04-05       Impact factor: 3.685
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.